MassHealth Drug Utilization Review (DUR) Program (800) 745-7318 (phone) (877) 208-7428 (fax)

## DUR BOARD MEETING (REMOTE) Quarterly Meeting June 8, 2022

# AGENDA

## I. Welcome and Introductory Remarks

- II. Resident Research Project: A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population This an overview of a research project developed by current pharmacy practice residents.
- III. Resident Research Project: Changes in Healthcare Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population

This an overview of a research project developed by current pharmacy practice residents.

## IV. Oncology Products: Indication Market Withdrawals

This overview will describe the pharmacy program response to the removal from the market of products which have received accelerated approval in the oncology therapeutic space.

#### V. MHDL Update

The MHDL Overview includes new additions, changes in Prior Authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.

## VI. DUR Operational Update

The DUR Operational Overview includes statistics associated with Prior Authorization (PA) review and PA response, and Call Center metrics

## VII. MassHealth Update

The MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.

#### VIII. Open Forum

#### IX. Narcolepsy Agents Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state. *(time permitting)* 

Zoom link: https://umassmed.zoom.us/j/92618015709?pwd=ZHhQVHR0OGhtVFR3QW5mUTM3V3dhdz09

The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at (617) 740-1600 VOICE and (617) 740-1700 TTY.

Next DUR Board (open meeting): September 14, 2022